Authors' recommendations: The included evidence shows that revascularisation rates with the Penumbra system are likely to exceed 80 per cent. Considering the results of case series that examine alternative thrombus clearing methods re-presented by the Penumbra Pivotal Stroke Trial Investigators (2009), the system compares favourably in terms of revascularisation rates. However, evidence from prospective randomised studies is lacking and the firm conclusions about clinical effectiveness of the Penumbra system remain dependent on the emergence of these trials. In particular, trials will require a focus on functional outcomes, as it has not been adequately substantiated that high revascularisation rates translate into long term reduction in patient disability and mortality. Thus any use of this intervention should be considered experimental.The low-level of available evidence makes the wider clinical impact of the Penumbra system uncertain at this stage. The technology has already begun to diffuse into the Australian health care system and has potential benefit to those patients who have ready access to the technology in terms of their proximity. The device is substantially more expensive than existing treatments. HealthPACT will seek the opinion of the Neurological Society of Australasia on the current state of the available evidence regarding the Penumbra.

Project Status: Completed

Year Published: 2010

URL for published report: Not Available

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Adelaide Health Technology Assessment

Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617

Contact Name: ahta@adelaide.edu.au

Contact Email: ahta@adelaide.edu.au

Copyright: Adelaide Health Technology Assessment (AHTA)